Cardiac resynchronization therapy and ventricular tachyarrhythmia burden.

Autor:	Tankut S; Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York. Electronic address: sinan_tankut@urmc.rochester.edu., Goldenberg I; Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York., Kutyifa V; Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York., Zareba W; Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York., Bragazzi NL; Laboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, Ontario, Canada., McNitt S; Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York., Huang DT; Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York., Aktas MK; Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York., Younis A; Clinical Cardiovascular Research Center, University of Rochester, Rochester, New York.
Jazyk:	angličtina
Zdroj:	Heart rhythm [Heart Rhythm] 2021 May; Vol. 18 (5), pp. 762-769. Date of Electronic Publication: 2021 Jan 11.
DOI:	10.1016/j.hrthm.2020.12.034
Abstrakt:	Background: Cardiac resynchronization therapy-defibrillator (CRT-D) may reduce the incidence of first ventricular tachyarrhythmia (VTA) in patients with heart failure (HF) and left bundle branch block (LBBB). Objective: The purpose of this study was to assess the effect of CRT-D on VTA burden in LBBB patients. Methods: We included 1281 patients with LBBB from MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). VTA was defined as any treated or monitored sustained ventricular tachycardia (VT ≥180 bpm) or ventricular fibrillation (VF). Life-threatening VTA was defined as VT ≥200 bpm or VF. VTA recurrence was assessed using the Andersen-Gill model. Results: During a mean follow-up of 2.5 years, 964 VTA episodes occurred in 264 patients (21%). The VTA rate per 100 person-years was significantly lower in the CRT-D group compared with the implantable cardioverter-defibrillator (ICD) group (20 vs 34; P <.01). Multivariate analysis demonstrated that CRT-D treatment was associated with a 32% risk reduction for VTA recurrence (hazard ratio 0.68; 95% confidence interval 0.57-0.82; P <.001), 57% risk reduction for recurrent life-threatening VTA, 54% risk reduction for recurrent appropriate ICD shocks, and 25% risk reduction for the combined endpoint of VTA and death. The effect of CRT-D on VTA burden was consistent among all tested subgroups but was more pronounced among patients in New York Heart Association functional class I. Landmark analysis showed that at 2 years, the cumulative probability of death subsequent to year one was highest (16%) among patients who had ≥2 VTA events during their first year. Conclusion: In patients with LBBB and HF, early intervention with CRT-D reduces mortality, VTA burden, and frequency of multiple appropriate ICD shocks. VTA burden is a powerful predictor of subsequent mortality. (Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu